Table 1.
Baseline characteristics of study patients (n = 73).
| SVR (n = 58) | non-SVR (n = 15) | p | |
|---|---|---|---|
| Sex (male/female) | 25/33 | 10/5 | 0.18 |
| Age (years) | 73 (38–87) * | 67 (50–86) * | 0.17 |
| Body mass index (kg/m2) | 22.9 (21.6–25.2) * | 25.3 (23.6–26.6) * | 0.043 |
| Chronic hepatitis/liver cirrhosis | 39/19 | 7/8 | 0.141 |
| History of HCC, n (%) | 13 (22.4) | 4 (26.7) | 0.996 |
| History of IFN treatments, n (%) | 37 (63.8) | 6 (40) | 0.095 |
| Platelet count (×103/μL) | 126 (99–167) * | 102 (83–152) * | 0.53 |
| Total bilirubin (mg/dL) | 0.6 (0.5–0.8) * | 0.7 (0.6–1.1) * | 0.072 |
| AST (IU/L) | 44 (34–57) * | 50 (40–66) * | 0.278 |
| ALT (IU/L) | 36 (27–50) * | 46 (39–58) * | 0.109 |
| Albumin (g/dL) | 4.2 (3.8–4.5) * | 4.2 (3.8–4.8) * | 0.547 |
| AFP > upper normal limit (10 ng/mL), n (%) | 20 (34.5) | 7 (46.7) | 0.141 |
| HCV RNA (log IU/mL) | 6.2 (5.8–6.6) * | 6.4 (6.1–6.5) * | 0.374 |
| Mac-2 binding protein (COI) | 3.27 (1.49–5.13) * | 2.35 (1.65–5.75) * | 0.881 |
| APRI | 1.1 (0.8–2.2) * | 2.0 (0.9–2.9) * | 0.309 |
| FIB-4 index | 3.67 (2.78–6.38) * | 4.53 (2.81–7.7) * | 0.482 |
| Resistance-associated substitutions, n (%) | |||
| L31V | 1 (1.7) | 2 (13.3) | 0.197 |
| Y93H | 16 (27.6) | 9 (60.0) | 0.04 |
* Interquartile range. AFP: α-Fetoprotein; ALT: Alanine aminotransferase; APRI: Asparate aminotransferase to platelet ratio index; AST: Aspartate aminotransferase; COI: Cutoff index; Fib-4: Fibrosis 4 index; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; IFN: Interferon.